J33

6,7-bis(chloranyl)-3,5-dihydro-1H-imidazo[2,1-b]quinazolin-2-one

Created:	2021-03-26
Last modified:	2021-09-29

Find Related PDB Entry
1 entries where J33 is found as a standalone ligand

Find related ligands: Help
Similar Ligands (Stereospecific) Similar Ligands (including Stereoisomers) Similar Ligands (Quick Screen) Similar Ligands (Substructure Stereospecific) Similar Ligands (Substructure including Stereoisomers)

Chemical Details
Formal Charge	0
Atom Count	23
Chiral Atom Count	0
Bond Count	25
Aromatic Bond Count	6

Toggle Hydrogen Toggle Labels

Chemical Component Summary
Name	6,7-bis(chloranyl)-3,5-dihydro-1H-imidazo[2,1-b]quinazolin-2-one
Systematic Name (OpenEye OEToolkits)	6,7-bis(chloranyl)-3,5-dihydro-1~{H}-imidazo[2,1-b]quinazolin-2-one
Formula	C₁₀ H₇ Cl₂ N₃ O
Molecular Weight	256.088
Type	NON-POLYMER

Chemical Descriptors
Type	Program	Version	Descriptor
SMILES	CACTVS	3.385	Clc1ccc2N=C3NC(=O)CN3Cc2c1Cl
SMILES	OpenEye OEToolkits	2.0.7	c1cc(c(c2c1N=C3NC(=O)CN3C2)Cl)Cl
Canonical SMILES	CACTVS	3.385	Clc1ccc2N=C3NC(=O)CN3Cc2c1Cl
Canonical SMILES	OpenEye OEToolkits	2.0.7	c1cc(c(c2c1N=C3NC(=O)CN3C2)Cl)Cl
InChI	InChI	1.03	InChI=1S/C10H7Cl2N3O/c11-6-1-2-7-5(9(6)12)3-15-4-8(16)14-10(15)13-7/h1-2H,3-4H2,(H,13,14,16)
InChIKey	InChI	1.03	OTBXOEAOVRKTNQ-UHFFFAOYSA-N

Drug Info: DrugBank

DrugBank data are sourced from datasets licensed under a Creative Common's Attribution-NonCommercial 4.0 International License

DrugBank ID	DB00261
Name	Anagrelide
Groups	investigational approved
Description	Anagrelide is a platelet-reducing agent used to lower dangerously elevated platelet levels (i.e. to treat thrombocythemia) in patients with myeloproliferative neoplasms.[L14153] It is an oral imidazoquinazoline that was first approved for use in the US in 1997.[A214274] It appears to carry a better response rate than other thrombocythemia treatments (e.g. [busulfan], [hydroxyurea]) and may be better tolerated.[A214274]
Synonyms	Anagrelida Anagrelide Anagrelide hydrochloride monohydrate Anagrelidum Anagrelide hydrochloride
Brand Names	Anagrelide Mylan Mylan-anagrelide Anagrelide Agrylin Dom-anagrelide Anagrelide Hydrochloride Xagrid PMS-anagrelide PHL-anagrelide Sandoz Anagrelide
Indication	Anagrelide is indicated for the treatment of thrombocythemia, secondary to malignant neoplasms, to reduce platelet count and the associated risk of thrombosis. It is also beneficial in the amelioration of thrombocythemia symptoms including thrombo-hemorrhagic events.[L14153]
Categories	Agents producing tachycardia Antineoplastic Agents Antineoplastic and Immunomodulating Agents Antiplatelet agents Cardiovascular Agents Cytochrome P-450 CYP1A2 Inhibitors Cytochrome P-450 CYP1A2 Inhibitors (weak) Cytochrome P-450 CYP1A2 Substrates Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic Index Cytochrome P-450 Enzyme Inhibitors Cytochrome P-450 Substrates Decreased Platelet Production Hematologic Agents Heterocyclic Compounds, Fused-Ring Highest Risk QTc-Prolonging Agents Narrow Therapeutic Index Drugs Phosphodiesterase 3 Inhibitors Phosphodiesterase Inhibitors Platelet-reducing Agents QTc Prolonging Agents Thrombocytosis
ATC-Code	L01XX35
CAS number	68475-42-3

Drug Targets

DrugBank data are sourced from datasets licensed under a Creative Common's Attribution-NonCommercial 4.0 International License

Name	Target Sequence	Pharmacological Action	Actions
cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A	MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDL...	unknown	inhibitor
Cytochrome P450 1A2	MALSQSVPFSATELLLASAIFCLVFWVLKGLRPRVPKGLKSPPEPWGWPL...	unknown	substrate,inhibitor

Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS. Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682